Zenas BioPharma, Inc.

Catalyst AI-extracted

obexelimab

Immunoglobulin G4-Related Disease (IgG4-RD)

Resolved

7days ago

Catalyst readout · ~ Jun 30, 2026 estimated

What's at stake A key catalyst for obexelimab (Immunoglobulin G4-Related Disease (IgG4-RD)) is expected ~ Jun 30, 2026.

Primary source · SEC 8-K verified 15h ago

“Zenas expects to submit a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) in the second quarter of 2026”